

*REMARKS/ARGUMENTS*

Claims 11-15, 25, 27, 32-34, 66-68, and 70-72 are pending. Claims 12-14 are amended herein. No new matter is added by way of these amendments.

Applicants acknowledge that claims 11, 15, 25, 27, 32-34, 66-68, and 70-72 are allowed


Claims 12-14 were rejected under 35 U.S.C. § 102(b) as allegedly anticipated by Gaudernack (WO 92/14756), Juretic (*Int. J. Cancer*, 68: 471-478 (1996)), and Gedde-Dahl (*Eur. J. Immunol.*, 23(3): 754-760 (1993)). Applicants traverse.

The Office Action states that claims 12-14 are directed to peptide fragments of SEQ ID NO: 15. However, claims 12-14 were amended in the Amendment and Reply dated February 26, 2007 to recite SEQ ID NO: 14. Accordingly, the cited art will be discussed with respect to SEQ ID NO: 14. The claims as amended herein recite fragments of SEQ ID NO: 14 that include the amino acid moiety Xaa<sub>1</sub>. None of the cited references discloses a fragment of SEQ ID NO: 14 that includes Xaa<sub>1</sub>. Therefore, the cited references do not anticipate the claimed invention.

Applicants respectfully request the withdrawal of this rejection.

Applicants respectfully submit that the patent application is in condition for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,

  
Jennifer M. Duk, Reg. No. 52,838  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-6731  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: August 31, 2007